Zur Rose Group: Charges in connection with mail-order of non-prescription drugs and electronic prescribing
EQS Group-News: Zur Rose Group AG
/ Key word(s): Legal Matter
Board of Directors of the Zur Rose Group stands resolutely behind CEO Walter Oberhänsli
Public prosecutor of the Canton of Thurgau files charges against Walter Oberhänsli in connection with mail-order of non-prescription drugs and electronic prescribing
The Kreuzlingen public prosecutor filed charges against Walter Oberhänsli in his capacity as CEO of the Zur Rose Group. The charges are based on a report of a criminal offence lodged by Pharmasuisse and relate to two separate issues: mail-order distribution of non-prescription drugs and rewarding doctors for issuing electronic prescriptions between 2010 and 2015. The Board of Directors vigorously rejects the accusations made against its CEO and has announced it will support Walter Oberhänsli unreservedly in fighting the charges made against him and protecting his integrity.
Mail-order distribution of non-prescription drugs
Cooperation with doctors to promote electronic prescribing
As the contested business activity was already discontinued five years ago, the Zur Rose Group rules out an impact of the proceedings on the current business performance.
Board of Directors stands unreservedly behind its CEO
Investors and analyst contact
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and has around seven million active customers in core European markets.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1034941|
|End of News||EQS Group News Service|